Patents by Inventor James LULO

James LULO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Claudin 18.2 multi-specific antibodies and uses thereof
    Patent number: 12780949
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions that can bind to the Claudin 18.2 protein. The multi-specific antibodies of the present technology are useful in methods for detecting and treating a Claudin 18.2-associated cancer in a subject in need thereof.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: November 3, 2026
    Assignee: ABPRO CORPORATION
    Inventors: Gang An, Zusheng Li, Yuan Liu, Adam Pelzek, Shaun Murphy, Lucy Zhang, Shengqin Wan, Yangde Chen, Marco Muda, James Lulo, Wei Li
  • CD3 TARGETING ANTIBODIES AND USES THEREOF
    Publication number: 20250340637
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD3 protein. The antibodies of the present technology are useful in methods for detecting CD3 and treating cancer in a subject in need thereof.
    Type: Application
    Filed: August 3, 2022
    Publication date: November 6, 2025
    Inventors: James Lulo, Marco Muda, Shaun Murphy, Adam Pelzek
  • METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION USING ANTI-ANG2 X VEGF MULTI-SPECIFIC ANTIBODIES
    Publication number: 20240158489
    Abstract: The present disclosure relates generally to methods for treating choroidal neovascularization in a subject in need thereof using anti-ANG-2×VEGF multi-specific antibodies.
    Type: Application
    Filed: March 29, 2022
    Publication date: May 16, 2024
    Inventors: Marco Muda, James Lulo
  • ANTI-CLAUDIN 18.2 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20230279152
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g multi-specific antibodies or antigen binding fragments thereof) that can bind to the Claudin 18.2 protein. The multi-specific antibodies of the present technology are useful in methods for detecting and treating a Claudin 18.2-associated cancer in a subject in need thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 7, 2023
    Inventors: Gang AN, Zusheng LI, Yuan LIU, Adam PELZEK, Shaun MURPHY, Lucy ZHANG, Shengqin WAN, Yangde CHEN, Marco MUDA, James LULO, Wei LI